LIOTHYRONINE SODIUM (liothyronine sodium) by Gen Pharmaceuticals is clinical pharmacology thyroid hormones enhance oxygen consumption by most tissues of the body and increase the basal metabolic rate and the metabolism of carbohydrates, lipids and proteins. Approved for the treatment of myxedema coma/precoma. First approved in 2005.
Drug data last refreshed 22h ago
CLINICAL PHARMACOLOGY Thyroid hormones enhance oxygen consumption by most tissues of the body and increase the basal metabolic rate and the metabolism of carbohydrates, lipids and proteins. In vitro studies indicate that T 3 increases aerobic mitochondrial function, thereby increasing the rates of…
Worked on LIOTHYRONINE SODIUM at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.